New Formula Developed by Rutgers Researcher Proves Promising in Alleviating Gastrointestinal Syndrome in Long-Haul COVID-19 Patient by Shifting Gut Microbiota
Rutgers University's Office for ResearchA Rutgers researcher’s new formula with Investigational New Drug (IND) status has successfully alleviated a patient’s long-term severe gastrointestinal (GI) illness associated with post-acute COVID-19 syndrome, or long-haul COVID, in a recent study. The study’s results on the formula developed by Liping Zhao, Ph.D., are now published in an article titled “Nutritional Modulation of Gut Microbiota Alleviates Severe Gastrointestinal Symptoms in a Patient with Post-Acute COVID-19 Syndrome” in mBio, a peer-reviewed journal of the American Society for Microbiology.